Urovant's overactive bladder drug scores in mid-stage trial
Urovant Sciences said its experimental overactive bladder drug vibegron improved symptoms in a large mid-stage study, a welcome signal for the company as it evaluates the drug further in a phase III initiated earlier this year.
The phase IIb two-stage trial enrolled more than 1,300 patients with OAB symptoms. In the first stage, patients either received once-daily oral vibegron (3 mg, 15 mg, 50 mg or 100 mg), the urinary incontinence drug tolterodine (4 mg); or a placebo for eight weeks. In the second stage, patients were given either vibegron (100 mg); tolterodine (4 mg); a combination vibegron (100 mg) and tolterodine (4 mg); or placebo for four weeks. The objective of the study was to evaluate the safety and efficacy of vibegron as a once-daily oral treatment for OAB patients, regardless of urge incontinence.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.